EML2 Antibody

What is EML2 and what cellular functions does it perform?

EML2 (Echinoderm Microtubule Associated Protein Like 2) is a tubulin binding protein that affects microtubule dynamics. It inhibits microtubule nucleation and growth, resulting in shorter microtubules . Recent research has discovered that EML2, particularly the shorter isoform (EML2-S), exhibits the unique ability to track the tips of shortening microtubules, a behavior not previously observed among human MAPs (Microtubule Associated Proteins) in vivo . EML2 is primarily localized in the cytoplasm, cytoskeleton, and spindle structures, where it colocalizes with the microtubule cytoskeleton and mitotic spindle .

What are the major isoforms of EML2 and how do they differ functionally?

EML2 exists in at least two major isoforms:

EML2-S is produced by alternative splicing and shows selective binding to Y-microtubules, while EML2-L (full-length) binds to both Y- and ΔY-microtubules . This differential binding preference contributes to their distinct roles in microtubule dynamics regulation.

What are the recommended dilution ratios for different applications of EML2 antibodies?

The optimal dilution ratios vary based on the specific application and antibody:

These dilution ranges should be used as starting points, and optimization might be necessary depending on your specific experimental conditions, sample type, and detection method .

How should EML2 antibodies be stored to maintain optimal activity?

Most EML2 antibodies should be stored at -20°C for long-term preservation, while short-term storage at 4°C is acceptable for antibodies in active use . The antibodies are typically supplied in buffer solutions containing stabilizers (such as 0.05% sodium azide) and glycerol (typically 50%), which helps prevent freeze-thaw damage . To maintain antibody integrity:

• Aliquot antibodies before freezing to minimize freeze-thaw cycles

• Avoid more than 5 freeze-thaw cycles as this can significantly reduce antibody activity

• When thawing, allow the antibody to reach room temperature naturally before use

• Return to appropriate storage temperature promptly after use

What blocking conditions are optimal for Western blotting with EML2 antibodies?

Based on validated protocols, the following blocking conditions have proven effective for Western blot applications with EML2 antibodies:

• Blocking buffer: 3% nonfat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20)

• Protein loading: 25μg per lane is typically sufficient for detection

• Secondary antibody: HRP-conjugated anti-species IgG at 1:10000 dilution

• Detection system: ECL (Enhanced Chemiluminescence) Basic Kit

• Exposure time: Approximately 90 seconds (may need adjustment based on signal strength)

These conditions have been validated on various cell lines and provide a good starting point, though optimization may be required for specific experimental systems.

How does EML2-S specifically recognize and bind to Y-microtubules?

EML2-S employs a sophisticated molecular mechanism to selectively bind Y-microtubules:

• The N-terminal β-propeller domain of EML2-S binds to the C-terminal tail (CTT) of α-tubulin through both electrostatic and hydrophobic interactions

• Critical to this binding are the R-patch (with key residues R69, R314, R316, and R341) and a hydrophobic "clamp" (involving residues L209 and Y254)

• Mutation studies have demonstrated that charge-reversal mutations (R69E) or alanine substitutions in the R-patch (2RA: R69A/R341A and 4RA: R69A/R314A/R316A/R341A) abolish microtubule binding

• Similarly, mutations in the hydrophobic clamp (L209R/Y254D) also prevent binding to microtubules

This specific recognition mechanism explains why EML2-S is largely excluded from the midbody in cytokinetic cells, which contains high levels of ΔY-microtubules, consistent with its binding preference for Y-microtubules .

What approaches can be used to distinguish between EML2 isoforms in experimental settings?

Researchers can employ several strategies to distinguish between EML2 isoforms:

When using tagged constructs, it's important to note that certain tags (like GFP or SNAP) can negatively impact EML2-S's ability to bind microtubules .

How can I troubleshoot unexpected band patterns in Western blots using EML2 antibodies?

Unexpected band patterns with EML2 antibodies can result from several factors:

• Multiple isoforms: EML2 exists in multiple isoforms (EML2-L, EML2-S) that appear as distinct bands. The calculated molecular weights are approximately 70 kDa, 86 kDa, and 92 kDa, but observed weights may differ .

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can alter protein mobility in gels, resulting in bands that differ from theoretical molecular weights.

• Proteolytic degradation: Sample preparation conditions may lead to partial protein degradation, resulting in multiple lower molecular weight bands.

• Non-specific binding: This can be addressed by:

  • Increasing antibody dilution (1:2000-1:3000 rather than 1:500)

  • Optimizing blocking conditions (3% nonfat dry milk in TBST has been validated)

  • Including additional washing steps between primary and secondary antibody incubations

  • Using lysates from EML2-knockdown cells as negative controls

• Cross-reactivity with other EML family members: EML family members (EML1-4) share conserved domains that might be recognized by some antibodies. Validate specificity through knockout/knockdown experiments or peptide competition assays.

What experimental controls should be included when using EML2 antibodies for the first time?

When validating a new EML2 antibody, include these essential controls:

• Positive control: Lysates from cells known to express EML2 (such as HCT116, HeLa cells)

• Negative control: One of the following:

  • Lysates from EML2-knockdown or knockout cells

  • Pre-incubation of the antibody with blocking peptide (if available)

  • Secondary antibody only (no primary antibody) to assess background

• Loading control: Use established housekeeping proteins (β-actin, GAPDH) to normalize expression levels

• Molecular weight marker: To verify the observed band size matches expected molecular weight

• Cross-validation: If possible, use two different antibodies targeting distinct epitopes of EML2 to confirm specificity

• Dilution series: Test multiple antibody dilutions (e.g., 1:500, 1:1000, 1:3000) to determine optimal signal-to-noise ratio

What considerations are important when designing experiments to investigate EML2's role in microtubule dynamics?

When investigating EML2's role in microtubule dynamics, researchers should consider:

• Isoform specificity: Design experiments that can distinguish between EML2-L and EML2-S functions, as they have different binding properties and potentially distinct roles in microtubule regulation

• Tubulin modification status: Since EML2-S preferentially binds Y-microtubules, the tyrosination state of tubulin in your experimental system is crucial. Consider using carboxypeptidase A (CPA) treatment to remove tyrosine residues for comparative studies

• Cell cycle stage: EML2 localizes differently during different cell cycle stages. In cytokinetic cells, EML2-S is excluded from the midbody, which contains high levels of ΔY-microtubules

• Live-cell imaging approach: To observe EML2's tracking of shortening microtubule tips, consider using fluorescently tagged constructs (note that GFP or SNAP tags may impact function) and high-resolution time-lapse microscopy

• Mutational analysis: The key residues involved in Y-microtubule binding (R69, R314, R316, R341, L209, Y254) can be mutated to assess functional consequences

• Interaction partners: Consider investigating how EML2 interacts with other MAPs and whether these interactions are affected by tubulin tyrosination status

How can researchers differentiate between direct and indirect effects when studying EML2's impact on cellular processes?

To distinguish direct from indirect effects of EML2 on cellular processes:

• In vitro reconstitution: Use purified recombinant EML2 proteins with purified tubulin to assess direct biochemical effects on microtubule assembly, dynamics, and stability in a minimal system

• Structure-function analysis: Generate and test domain-specific mutants or truncated forms of EML2 to map which regions are responsible for specific activities

• Acute vs. chronic manipulation: Compare acute depletion techniques (e.g., auxin-inducible degron system) with long-term knockdown or knockout to distinguish immediate direct effects from compensatory responses

• Rescue experiments: After EML2 depletion, reintroduce either wild-type or mutant versions to determine which domains/functions are essential for phenotype rescue

• Temporal analysis: In time-course experiments, direct effects typically manifest before indirect effects

• Combined approaches: Use complementary techniques (biochemistry, live imaging, genetic manipulation) to build a coherent model of EML2 function

How should researchers interpret differences between published molecular weights and observed bands when using EML2 antibodies?

When observed molecular weights differ from published values, consider these explanations:

• Isoform variation: The calculated molecular weights for EML2 isoforms range from 70-92 kDa. Observed variations could reflect detection of different isoforms. EML2-L appears as a higher molecular weight band compared to EML2-S

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can alter protein mobility. Western blotting is based on the specific binding of antigen and antibody, and the mobility is affected by many factors which may cause the observed band size to be inconsistent with the expected size

• Technical variations: SDS-PAGE conditions (percentage, buffer system), sample preparation methods, and gel run time can all affect apparent molecular weight

• Antibody specificity: Different antibodies may recognize specific regions, domains, or epitopes that are differently accessible in various isoforms or modified forms

• Reference standards: Ensure your molecular weight markers are accurately calibrated and appropriate for your gel percentage

If consistent discrepancies are observed, consider additional validation approaches such as mass spectrometry or immunoprecipitation followed by Western blotting to confirm the identity of the observed protein .

What are the implications of EML2's interaction with microtubules for broader cellular processes?

EML2's microtubule interactions have significant implications for:

• Cell Division: As EML2 localizes to the spindle during mitosis but EML2-S is excluded from the midbody during cytokinesis, it likely plays stage-specific roles in cell division

• Microtubule Network Organization: By inhibiting microtubule nucleation and growth, EML2 contributes to regulating microtubule length and network architecture

• Microtubule Dynamics Sensing: EML2-S's unique ability to track shortening microtubule tips suggests it may function as a sensor of microtubule depolymerization, potentially connecting this process to downstream signaling pathways

• Spatial Regulation of Microtubule Populations: The preferential binding of EML2-S to Y-microtubules suggests involvement in spatially regulating distinct microtubule populations based on their tyrosination status

• Cell Motility and Polarity: Given the importance of properly regulated microtubule dynamics for cell migration and polarity, EML2's activities likely influence these processes

• Neurodevelopment: The classification of EML2 as relevant to neuroscience research suggests potential roles in neuronal development or function where microtubule dynamics are critically important

Understanding these broader implications provides context for experimental results and helps guide hypothesis generation for future studies.

What unresolved questions remain regarding EML2's cellular functions and interactions?

Several important questions remain to be fully addressed:

• Regulatory mechanisms: How is EML2's microtubule-binding activity regulated? Are there specific kinases, phosphatases, or other post-translational modifications that modulate its function?

• Isoform-specific functions: What are the distinct biological roles of EML2-L versus EML2-S beyond their differential microtubule binding preferences?

• Interaction network: What proteins interact with EML2, and do these interactions differ between isoforms or cell cycle stages?

• Tissue-specific roles: Given its relevance to neuroscience research, does EML2 have specialized functions in neuronal cells compared to other cell types?

• Disease associations: Are alterations in EML2 expression or function associated with specific pathological conditions?

• Evolutionary conservation: How conserved are EML2's functions across species, and what can this tell us about its fundamental biological importance?

• Signaling integration: Does EML2 connect microtubule dynamics to specific cellular signaling pathways?

Addressing these questions will require integrating advanced imaging techniques, biochemical approaches, and genetic manipulation strategies.

What emerging techniques might enhance our understanding of EML2 function?

Cutting-edge approaches with potential to advance EML2 research include:

• Cryo-electron microscopy: To determine the precise structural basis for EML2's interaction with microtubules at near-atomic resolution

• Super-resolution microscopy techniques (STORM, PALM, STED): To visualize EML2's dynamic interactions with microtubules beyond the diffraction limit

• Proximity labeling (BioID, APEX): To identify proteins that interact with EML2 in their native cellular context

• Optogenetic approaches: To acutely manipulate EML2 activity in specific subcellular regions

• CRISPR-based screening: To identify genetic interactions and pathways connected to EML2 function

• Single-molecule tracking: To analyze the kinetics of EML2's association with and dissociation from microtubules

• Computational modeling: To predict how EML2 affects microtubule network architecture and dynamics across different cellular contexts

• Organoid systems: To study EML2's functions in more physiologically relevant 3D tissue contexts

These approaches could provide unprecedented insights into EML2's cellular roles and mechanisms of action.

How might fundamental research on EML2 translate to potential therapeutic applications?

While current research on EML2 is primarily fundamental, potential translational directions include:

• Cancer therapeutics: If EML2's role in regulating microtubule dynamics impacts cell division or metastasis, it could represent a novel target for cancer treatment approaches

• Neurodegenerative diseases: Given EML2's relevance to neuroscience research and microtubule regulation, it may have implications for conditions involving cytoskeletal dysfunction in neurons

• Diagnostic biomarkers: Patterns of EML2 expression or post-translational modification could potentially serve as biomarkers for specific disease states

• Drug delivery strategies: Understanding EML2's interactions with the microtubule network could inform the development of drug delivery systems that leverage cytoskeletal transport

• Regenerative medicine: If EML2 influences cell migration or differentiation through cytoskeletal regulation, this knowledge could be applied to tissue engineering approaches